National Blood Authority

Entity resources and planned performance

# National Blood Authority

[Section 1: Entity overview and resources 304](#_Toc117407391)

[1.1 Strategic direction statement 304](#_Toc117407392)

[1.2 Entity resource statement 305](#_Toc117407393)

[1.3 Budget measures 307](#_Toc117407394)

[Section 2: Outcomes and planned performance 308](#_Toc117407395)

[2.1 Budgeted expenses and performance 308](#_Toc117407396)

[Section 3: Budgeted financial statements 314](#_Toc117407397)

[3.1 Budgeted financial statements 314](#_Toc117407398)

[3.2 Budgeted financial statements tables 315](#_Toc117407399)

## Section 1: Entity overview and resources

### 1.1 Strategic direction statement[[1]](#footnote-1)

The focus of the National Blood Authority (NBA) is saving and improving Australian lives through a world-class blood supply. On behalf of all Australian governments, the NBA pursues this focus through the following 5 strategies:

* Provide a safe, secure and affordable supply of blood and blood-related products and services.
* Drive performance improvement in the Australian blood sector.
* Promote a best practice model of management and use of blood and
blood-related products and services.
* Develop policy and provide policy advice on the sustainability of the blood sector.
* Be a high performing organisation.

In 2022–23, the NBA will continue to negotiate and manage critical contracts for the ongoing supply of fresh blood, as well as for products including fractionated and recombinant blood products[[2]](#footnote-2). This includes managing the Deed of Agreement for all blood and related services from the Australian Red Cross Lifeblood (Lifeblood), and managing the substantial funding provided by the Australian Government and state and territory governments for Lifeblood’s operations. It also includes substantial contracts with domestic and multi-national commercial suppliers of blood-related products.

The NBA will continue to work with all Australian governments and stakeholders to implement an efficient, demand-driven blood supply system that is highly responsive to clinical needs and based on evidence and good clinical practice. The NBA will undertake work to improve the clinical use of blood and blood‑related products, respond to new and emerging evidence, assess and review new products and therapies, and recognise the growing cost of blood products and the challenges of global supply and demand issues for plasma-derived products.

The role and functions of the NBA are set out in the *National Blood Authority Act 2003*. The NBA is a non-corporate Commonwealth entity under the *Public Governance, Performance and Accountability Act 2013*.

### 1.2 Entity resource statement

Table 1.1 shows the total funding from all sources available to the entity for its operations and to deliver programs and services on behalf of the Government.

The table summarises how resources will be applied by outcome (government strategic policy objectives) and by administered (on behalf of the Government or the public) and departmental (for the entity’s operations) classification.

For more detailed information on special accounts and special appropriations, refer to *Budget Paper No. 4 – Agency Resourcing*.

Information in this table is presented on a resourcing (that is, appropriations/cash available) basis, whilst the ‛Budgeted expenses by outcome’ tables in Section 2 and the financial statements in Section 3 are presented on an accrual basis.

Table 1.1: NBA resource statement – Budget estimates for 2022–23 as at October Budget 2022

|  |  |  |
| --- | --- | --- |
|  | **2021–22 Estimated actual**$'000 | **2022–23Estimate**$'000 |
| **DEPARTMENTAL** |  |   |
| Prior year appropriation available | 1,339 | 1,339 |
| **Annual appropriations** |  |  |
| Ordinary annual services (a) |  |  |
| Departmental appropriation | 5,513 | 5,479 |
| s74 retained revenue receipts (b) | 255 | 250 |
| Departmental Capital Budget (c) | 645 | 651 |
| Other services (d) |  |   |
| Equity injection | - | - |
| **Total departmental annual appropriations** | **6,413** | **6,380** |
| **Special accounts (e)** |  |  |
| Opening balance | 7,710 | 6,990 |
| Appropriation receipts | 6,413 | 6,380 |
| Non-appropriation receipts  | 4,943 | 3,566 |
| **Total special account** | **11,356** | **9,946** |
| Less appropriations drawn from annual or special appropriations above and credited to special accounts (f) | (6,413) | (6,380) |
| **Total departmental resourcing**  | **12,695** | **11,285** |

Table 1.1: NBA resource statement – Budget estimates for 2022–23 as at October Budget 2022 (continued)

|  |  |  |
| --- | --- | --- |
|  | **2021–22 Estimated actual**$'000 | **2022–23Estimate**$'000 |
| **ADMINISTERED** |  |   |
| **Annual appropriations** |  |   |
| Ordinary annual services (a) |  |   |
| Outcome 1 | 343 | 184 |
| Other services (d) |  |   |
| Administered assets and liabilities | - | - |
| **Total administered annual appropriations** | **343** | **184** |
| **Special accounts (e)** |  |  |
| Opening balance  | 138,786 | 182,356 |
| Appropriation receipts | 343 | 184 |
| Appropriation receipts - other entities (g) | - | 531 |
| Non-appropriation receipts  | 1,536,635 | 1,564,180 |
| **Total special accounts** | **1,536,978** | **1,564,895** |
| Less appropriations drawn from annual or special appropriations above and credited to special accounts (f) | (343) | (184) |
| **Total administered resourcing**  | **1,536,978** | **1,564,895** |
| **Total resourcing for NBA** | **1,549,673** | **1,576,180** |
|  |  |  |
|  | **2021–22** | **2022–23** |
| **Average staffing level (number)** | 60 | 52 |

All figures are GST exclusive.

(a) Appropriation Bill (No. 1) 2022–23, Supply Bill (No.3) 2022–23 and *Supply Act (No.1) 2022–23*.

(b) Estimated retained revenue receipts under section 74 of the *Public Governance, Performance and Accountability Act 2013* (PGPA Act).

(c) Departmental Capital Budgets (DCB) are not separately identified in Appropriation Bill (No.1) and form part of ordinary annual services items. Please refer to Table 3.5 within this chapter for further details. For accounting purposes, this amount has been designated as a 'contribution by owner'.

(d) Appropriation Bill (No. 2) 2022–23.

(e) For further information on special appropriations and special accounts, please refer to *Budget Paper No. 4 - Agency Resourcing*. Also see Table 2.1 within this chapter for further information on outcome and program expenses broken down by various funding sources, e.g. annual appropriations, special appropriations and special accounts.

(f) Appropriation receipts included above.

(g) Appropriation receipts from the Department of Health and Aged Care.

### 1.3 Budget measures

Budget measures in Part 1 relating to the NBA are detailed in *Budget Paper No. 2* and are summarised below.

Table 1.2: NBA October 2022–23 Budget measures

Part 1. Measures announced since the March 2022–23 Budget

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|   | **Program** | **2021–22**$'000 | **2022–23**$'000 | **2023–24**$'000 | **2024–25**$'000 | **2025–26**$'000 |
| **An Ambitious and Enduring APS Reform Plan (a)** |  |  |  |
| National Blood Authority |  |  |   |  |  |  |
| Departmental payments | 1.1 | - | (2) | (6) | (7) | - |
| **Total**  |  | **-** | **(2)** | **(6)** | **(7)** | **-** |
| **Savings from External Labour, and Savings from Advertising, Travel and Legal Expenses (a)** |
| National Blood Authority |  |  |   |  |  |  |
| Departmental payments | 1.1 | - | (76) | - | - | - |
| **Total**  |  | **-** | **(76)** | **-** | **-** | **-** |

(a) The NBA is not the lead entity for these measures. NBA impacts only are shown in this table.

## Section 2: Outcomes and planned performance

Government outcomes are the intended results, impacts or consequences of actions by the Government on the Australian community. Commonwealth programs are the primary vehicle by which government entities achieve the intended results of their outcome statements. Entities are required to identify the programs which contribute to government outcomes over the Budget and forward years.

Each outcome is described below together with its related programs. The following provides detailed information on expenses for each outcome and program, further broken down by funding source.

**Note:**

Performance reporting requirements in the Portfolio Budget Statements are part of the Commonwealth Performance Framework established by *the Public Governance, Performance and Accountability Act 2013*. It is anticipated that the performance measures described in Portfolio Budget Statements will be read with broader information provided in an entity’s Corporate Plan and Annual Performance Statement – included in Annual Reports – to provide an entity’s complete performance story.

The NBA’s most recent Corporate Plan and Annual Performance Statement are available at: www.blood.gov.au/about-nba

### 2.1 Budgeted expenses and performance

**Outcome 1**

Access to a secure supply of safe and affordable blood products, including through national supply arrangements and coordination of best practice standards within agreed funding policies under the national blood arrangements

#### Program contributing to Outcome 1

**Program 1.1: National Blood Agreement Management**

#### Linked programs

| Other Commonwealth entities that contribute to Outcome 1 |
| --- |
| Australian Commission on Safety and Quality in Health Care (ACSQHC)[[3]](#footnote-3) |
| Program 1.1: Safety and Quality in Health CareThe ACSQHC works closely with the NBA in relation to the *National Safety and Quality Health Service Standard 7: Blood Management.* This supports the NBA in administering the National Blood Agreement. |
| Department of Health and Aged Care |
| Program 1.1: Health Research, Coordination and AccessThe Department of Health and Aged Care, in collaboration with state and territory governments, has policy responsibility for ensuring Australians have access to an adequate, safe, secure and affordable blood supply. This includes supporting the NBA to administer the national blood arrangements. |

*Budgeted expenses for Outcome 1*

This table shows how much the entity intends to spend (on an accrual basis) on achieving the outcome, broken down by program, as well as by Administered and Departmental funding sources.

Table 2.1.1: Budgeted expenses for Outcome 1

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual**$'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate**$'000 | **2024–25 Forward estimate**$'000 | **2025–26 Forward estimate**$'000 |
| **Program 1.1: National Blood Agreement Management** |
| Administered expenses |  |   |  |  |  |
| Ordinary annual services (a) | 343 | 184 | - | - | - |
| to National Blood Authority Account | (343) | (184) | - | - | - |
| to National Managed Fund (Blood and Blood Products) Special Account | - | - | - | - | - |
| Special accounts |  |   |  |  |  |
| National Blood Authority Account | 1,399,495 | 1,579,416 | 1,670,875 | 1,773,067 | 1,950,173 |
| National Managed Fund (Blood and Blood Products) Special Account | - | - | - | - | - |
| Departmental expenses |  |   |  |  |  |
| Departmental appropriation (b) | 5,513 | 5,479 | 5,718 | 5,786 | 5,844 |
| to National Blood Authority Account | (5,513) | (5,479) | (5,718) | (5,786) | (5,844) |
| Special accounts |  |   |  |  |  |
| National Blood Authority Account | 10,731 | 9,372 | 9,723 | 9,809 | 9,711 |
| Expenses not requiring appropriation in the Budget year (c) | 667 | 865 | 1,324 | 1,324 | 1,324 |
| Operating deficit (surplus) | (139) | - | - | - | - |
| **Total for Program 1.1** | **1,410,754** | **1,589,653** | **1,681,922** | **1,784,200** | **1,961,208** |
| **Total expenses for Outcome 1** | **1,410,754** | **1,589,653** | **1,681,922** | **1,784,200** | **1,961,208** |
|  |  |  |  |  |  |
|  | **2021–22** | **2022–23** |  |  |  |
| **Average staffing level (number)** | 60 | 52 |  |  |  |

 (a) Appropriation Bill (No. 1) 2022–23.

(b) Departmental appropriation combines 'Ordinary annual services Appropriation Bill (No. 1)' and 'Revenue from independent sources (s74)'.

(c) Expenses not requiring appropriation in the Budget year are made up of depreciation expense, amortisation expense, makegood expense and audit fees.

#### Performance measures for Outcome 1

Table 2.1.2 details the performance measures for each program associated with Outcome 1. It also provides the related key activities as expressed in the current corporate plan where further detail is provided about the delivery of the activities related to the program, the context in which these activities are delivered and how the performance of these activities will be measured. Where relevant, details of the October 2022-23 Budget measures that have created new programs or materially changed existing programs are provided.

Table 2.1.2: Performance measures for the NBA

|  |
| --- |
| Outcome 1 |
| Access to a secure supply of safe and affordable blood products, including through national supply arrangements and coordination of best practice standards within agreed funding policies under the national blood arrangements |
| Program Objective – Program 1.1: National Blood Agreement Management |
| The National Blood Authority is a statutory entity that manages and coordinates arrangements for the supply of blood and blood-related products and services on behalf of all Australian governments in accordance with the National Blood Agreement.The primary objectives of the National Blood Agreement are to:* provide an adequate, safe, secure and affordable supply of blood and blood-related products and services
* promote the safe, high quality management and use of blood and blood-related products and services in Australia.
 |
| Key Activities |
| * Provide a safe, secure and affordable supply of blood and blood-related products and services.
* Drive performance improvement in the Australian blood sector.
* Promote a best practice model of management and use of blood andblood-related products and services.
* Develop policy and provide policy advice on the sustainability of the blood sector.
* Be a high performing organisation.
 |
| Performance Measures |
| A safe, secure and affordable supply of blood and blood-related products for Australia. |
| Prior Year2021–22 Expected Performance Results | Budget Year2022–23 Planned Performance Results  | Forward Estimates2023–26 Planned Performance Results |
| Blood and blood-related products were available to meet clinical requirements.There were no events during the reporting period that required the National Blood Supply Contingency Plan to be activated.Multiple contracts from diverse sources for relevant blood products were in place and managed to ensure security of supply. | Blood and blood-related products are available to meet clinical requirements.Events that activate the National Blood Supply Contingency Plan, if any, are managed effectively and efficiently by the NBA. Multiple contracts from diverse sources for relevant blood products are in place and managed to ensure security of supply. | As per 2022–23. |
| The supply outcome is within 5% of the National Supply Plan & Budget approved by governments.  |
| Prior Year2021–22 Planned Performance Results | Budget Year2022–23 Planned Performance Result | Forward Estimates2023–24 Planned Performance Result | Forward Estimates2024–25 Planned Performance Result | Forward Estimates2025–26 Planned Performance Result |
| <5% variation | <5% variation | <5% variation | <5% variation | <5% variation |
| Prior Year2021–22 Expected Performance Results |
| -1.8% variation |

|  |
| --- |
| Appropriate access and use of immunoglobulin (Ig), as indicated by clinical demand against approved access criteria[[4]](#footnote-4).  |
| Prior Year2021–22 Planned Performance Result | Budget Year2022–23 Planned Performance Result | Forward Estimates2023–24 Planned Performance Result | Forward Estimates2024–25 Planned Performance Result | Forward Estimates2025–26 Planned Performance Result |
| <10% growth in Ig demand under approved criteria | <9% growth in Ig demand under approved criteria | <8% growth in Ig demand under approved criteria | <8% growth in Ig demand under approved criteria | <8% growth in Ig demand under approved criteria |
| Prior Year2021–22 Expected Performance Results |
| 6.9% growth in Igdemand under approved criteria |
| National performance reporting and benchmarking across the Australian blood sector. |
| Prior Year2021–22 Expected Performance Results | Budget Year2022–23 Planned Performance Results  | Forward Estimates2023–26 Planned Performance Results |
| Published performance reporting and benchmarking information on the NBA website for the blood sector community.[[5]](#footnote-5) | Publish performance reporting and benchmarking information on the NBA website for the blood sector community.[[6]](#footnote-6) | As per 2022–23. |
| Material changes to Program 1.1 resulting from the following measures:There are no material changes to Program 1.1 resulting from measures. |

## Section 3: Budgeted financial statements

Section 3 presents budgeted financial statements which provide a comprehensive snapshot of entity finances for the 2022–23 Budget year, including the impact of budget measures and resourcing on financial statements.

### 3.1 Budgeted financial statements

#### 3.1.1 Differences between entity resourcing and financial statements

This section is not applicable to the NBA.

#### 3.1.2 Explanatory notes and analysis of budgeted financial statements

#### Departmental resources

##### **Comprehensive Income Statement**

This statement illustrates the expected financial results for the NBA by identifying accrual expenses and revenues showing the net cost of services.

The NBA’s operational costs are funded jointly by the Australian Government and state and territory governments on a 63%: 37% basis via annual contributions. All NBA receipts and payments are accounted for through special accounts.

The income statement deficit in the Budget year and forward years is a result of the Government’s decision to no longer fund for depreciation via an operating appropriation.

##### **Balance Sheet**

Special account accumulated funds are held within the Official Public Account and included as cash and cash equivalents in the Balance Sheet. The NBA always maintains sufficient accumulated funds to cover employee entitlements and other liabilities.

##### **Administered Resources**

*Schedule of Budgeted Income and Expenses Administered on Behalf of Government*

The NBA’s administered accounts include contributions from all states and territories and the Australian Government for the supply of blood and blood related products for 2022–23. Each year, the NBA formulates the National Supply Plan and Budget, which is derived from demand estimates provided by the states and territories.

###### *Schedule of Budgeted Assets and Liabilities Administered on Behalf of Government*

The schedule of budgeted assets and liabilities administered on behalf of Government illustrates normal movements in non-financial assets and liabilities. Special account accumulated funds are held within the Official Public Account and included as Cash and cash equivalents in the Balance Sheet. The balance of Receivables represents GST payments made to suppliers which are recoverable from the Australian Taxation Office.

### 3.2 Budgeted financial statements tables

**Table 3.1: Comprehensive income statement (showing net cost of services) for the period ended 30 June**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual**$'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate**$'000 | **2024–25 Forward estimate**$'000 | **2025–26 Forward estimate**$'000 |
| **EXPENSES** |  |   |   |   |   |
| Employee benefits | 7,683 | 6,498 | 6,886 | 6,886 | 6,886 |
| Supplier expenses | 2,003 | 2,143 | 2,040 | 2,126 | 2,028 |
| Depreciation and amortisation | 1,541 | 1,566 | 2,091 | 2,091 | 2,091 |
| Interest on RoU | 8 | 25 | 25 | 25 | 25 |
| Finance costs | - | 5 | 5 | 5 | 5 |
| Loss on sale of assets | 24 | - | - | - | - |
| **Total expenses** | **11,259** | **10,237** | **11,047** | **11,133** | **11,035** |
| **LESS:**  |  |  |  |  |  |
| **OWN-SOURCE INCOME** |  |  |  |  |  |
| **Revenue** |  |  |  |  |  |
| Sale of goods and rendering of services | 255 | 250 | 250 | 250 | - |
| Other revenue | 4,710 | 3,656 | 3,755 | 3,773 | 3,867 |
| **Total revenue** | **4,965** | **3,906** | **4,005** | **4,023** | **3,867** |
| **Gains** |  |  |  |  |  |
| Other | 66 | 66 | 66 | 66 | 66 |
| **Total gains** | **66** | **66** | **66** | **66** | **66** |
| **Total own-source income** | **5,031** | **3,972** | **4,071** | **4,089** | **3,933** |
| **Net cost of (contribution by) services**  | **6,228** | **6,265** | **6,976** | **7,044** | **7,102** |
| Revenue from Government | 5,513 | 5,479 | 5,718 | 5,786 | 5,844 |
| **Surplus (deficit)** | **(715)** | **(786)** | **(1,258)** | **(1,258)** | **(1,258)** |
| **Surplus (deficit) attributable to the Australian Government** | **(715)** | **(786)** | **(1,258)** | **(1,258)** | **(1,258)** |
| **OTHER COMPREHENSIVE INCOME** |  |  |  |  |  |
| Changes in asset revaluation reserves | - | - | - | - | - |
| **Total other comprehensive income**  | **-** | **-** | **-** | **-** | **-** |
| **Total comprehensive income attributable to the Australian Government** | **(715)** | **(786)** | **(1,258)** | **(1,258)** | **(1,258)** |
| **Note: Reconciliation of comprehensive income attributable to the agency** |   |
|  | **2021–22** $'000 | **2022–23** $'000 | **2023–24** $'000 | **2024–25** $'000 | **2025–26** $'000 |
| **Total comprehensive income (loss) attributable to the Australian Government** | **(715)** | **(786)** | **(1,258)** | **(1,258)** | **(1,258)** |
| plus non-appropriated expenses depreciation and amortisation expenses | 577 | 799 | 1,258 | 1,258 | 1,258 |
| plus depreciation and amortisation expenses for RoU | 964 | 767 | 833 | 833 | 833 |
| less lease principal repayments | (965) | (780) | (833) | (833) | (833) |
| **Total comprehensive income (loss) attributable to the agency** | **(139)** | **-** | **-** | **-** | **-** |

RoU = Right-of-Use asset

**Table 3.2: Budgeted departmental balance sheet (as at 30 June)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual**$'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate**$'000 | **2024–25 Forward estimate**$'000 | **2025–26 Forward estimate**$'000 |
| **ASSETS** |   |   |   |   |   |
| **Financial assets** |  |   |  |  |  |
| Cash and cash equivalents | 6,990 | 2,874 | 2,879 | 2,884 | 2,889 |
| Receivables | 1,848 | 1,848 | 1,848 | 1,848 | 1,848 |
| **Total financial assets** | **8,838** | **4,722** | **4,727** | **4,732** | **4,737** |
| **Non-financial assets** |  |   |  |  |  |
| Land and buildings | 6,289 | 7,111 | 5,640 | 4,169 | 2,698 |
| Property, plant and equipment | 528 | 2,863 | 2,738 | 2,625 | 2,507 |
| Intangibles | 55 | 99 | 260 | 415 | 574 |
| Other | 189 | 189 | 189 | 189 | 189 |
| **Total non-financial assets** | **7,061** | **10,262** | **8,827** | **7,398** | **5,968** |
| **Total assets** | **15,899** | **14,984** | **13,554** | **12,130** | **10,705** |
| **LIABILITIES** |  |   |  |  |  |
| **Payables** |  |   |  |  |  |
| Suppliers | 109 | 104 | 104 | 104 | 104 |
| Other payables | 610 | 610 | 610 | 610 | 610 |
| **Total payables** | **719** | **714** | **714** | **714** | **714** |
| **Interest bearing liabilities** |  |   |  |  |  |
| Leases | 4,965 | 4,185 | 3,352 | 2,519 | 1,686 |
| **Total interest bearing liabilities** | **4,965** | **4,185** | **3,352** | **2,519** | **1,686** |
| **Provisions** |  |   |  |  |  |
| Employees | 1,897 | 1,897 | 1,897 | 1,897 | 1,897 |
| Other provisions | - | 5 | 10 | 15 | 20 |
| **Total provisions** | **1,897** | **1,902** | **1,907** | **1,912** | **1,917** |
| **Total liabilities** | **7,581** | **6,801** | **5,973** | **5,145** | **4,317** |
| **Net Assets** | **8,318** | **8,183** | **7,581** | **6,985** | **6,388** |
| **EQUITY** |  |   |  |  |  |
| Contributed equity | 7,089 | 7,740 | 8,396 | 9,058 | 9,719 |
| Reserves | 619 | 619 | 619 | 619 | 619 |
| Retained surpluses or (accumulated deficits) | 610 | (176) | (1,434) | (2,692) | (3,950) |
| **Total equity** | **8,318** | **8,183** | **7,581** | **6,985** | **6,388** |

**Table 3.3: Departmental statement of changes in equity — summary of movement (Budget year 2022–23)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Retained earnings** $'000 | **Asset revaluation reserve** $'000 | **Contributed equity/capital** $'000 | **Total equity** $'000 |
| **Opening balance as at 1 July 2022** |  |  |  |  |
| Balance carried forward from previous period | 610 | 619 | 7,089 | **8,318** |
| Surplus (deficit) for the period | (786) | - | - | **(786)** |
| Appropriation (equity injection) | - | - | - | **-** |
| Capital budget - Bill 1 (DCB) | - | - | 651 | **651** |
| **Estimated closing balance as at30 June 2023** | **(176)** | **619** | **7,740** | **8,183** |

DCB = Departmental Capital Budget

**Table 3.4: Budgeted departmental statement of cash flows (for the period ended 30 June)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual**$'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate**$'000 | **2024–25 Forward estimate**$'000 | **2025–26 Forward estimate**$'000 |
| **OPERATING ACTIVITIES** |   |   |   |   |   |
| **Cash received** |  |   |  |  |  |
| Appropriations | 5,120 | 5,479 | 5,718 | 5,786 | 5,844 |
| Good and services | 235 | 250 | 250 | 250 | - |
| Other cash received | 4,710 | 3,656 | 3,755 | 3,773 | 3,867 |
| Net GST received | 8 | - | - | - | - |
| **Total cash received** | **10,073** | **9,385** | **9,723** | **9,809** | **9,711** |
| **Cash used** |  |   |  |  |  |
| Employees | 7,985 | 6,498 | 6,886 | 6,886 | 6,886 |
| Suppliers | 1,741 | 2,082 | 1,974 | 2,060 | 1,962 |
| Interest payments on lease liability | 8 | 25 | 25 | 25 | 25 |
| Net GST paid | - | - | - | - | - |
| **Total cash used** | **9,734** | **8,605** | **8,885** | **8,971** | **8,873** |
| **Net cash from (or used by) operating activities** | **339** | **780** | **838** | **838** | **838** |
| **INVESTING ACTIVITIES** |  |   |  |  |  |
| **Cash received** |  |   |  |  |  |
| Other cash received | - | - | - | - | - |
| **Total cash received** | **-** | **-** | **-** | **-** | **-** |
| **Cash used** |  |   |  |  |  |
| Purchase of property, plant and equipment | 1,082 | 4,767 | 656 | 662 | 661 |
| **Total cash used** | **1,082** | **4,767** | **656** | **662** | **661** |
| **Net cash from (or used by) investing activities** | **(1,082)** | **(4,767)** | **(656)** | **(662)** | **(661)** |
| **FINANCING ACTIVITIES** |  |   |  |  |  |
| **Cash received** |  |   |  |  |  |
| Capital budget - Bill 1 (DCB) | 645 | 651 | 656 | 662 | 661 |
| **Total cash received** | **645** | **651** | **656** | **662** | **661** |
| **Cash used** |  |   |  |  |  |
| Lease principal repayments | 965 | 780 | 833 | 833 | 833 |
| **Total cash used** | **965** | **780** | **833** | **833** | **833** |
| **Net cash from (or used by) financing activities** | **(320)** | **(129)** | **(177)** | **(171)** | **(172)** |
| **Net increase (or decrease) in cash held** | **(1,063)** | **(4,116)** | **5** | **5** | **5** |
| Cash and cash equivalents at the beginning of the reporting period | 8,053 | 6,990 | 2,874 | 2,879 | 2,884 |
| **Cash and cash equivalents at the end of the reporting period** | **6,990** | **2,874** | **2,879** | **2,884** | **2,889** |

DCB = Departmental Capital Budget

**Table 3.5: Departmental capital budget statement (for the period
ended 30 June)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual**$'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate**$'000 | **2024–25 Forward estimate**$'000 | **2025–26 Forward estimate**$'000 |
| **CAPITAL APPROPRIATIONS** |   |  |  |   |   |
| Capital budget - Bill 1 (DCB) | 645 | 651 | 672 | 681 | 681 |
| Equity injections - Bill 2 | - | - | - | - | - |
| **Total capital appropriations** | **645** | **651** | **672** | **681** | **681** |
| **Total new capital appropriations represented by:** |   |   |  |   |   |
| Purchase of non-financial assets | 645 | 651 | 672 | 681 | 681 |
| **Total items** | **645** | **651** | **672** | **681** | **681** |
| **PURCHASE OF NON-FINANCIAL ASSETS** |   |  |  |  |   |
| Funded by capital appropriation - DCB (a) | 645 | 652 | 672 | 681 | 681 |
| Funded internally from departmental resources | - | - | - | - | - |
| **Total acquisitions of non-financial assets** | **645** | **652** | **672** | **681** | **681** |
| **RECONCILIATION OF CASH USED TO ACQUIRE ASSETS TO ASSET MOVEMENT TABLE** |  |  |  |  |  |
| Total purchases | 1,082 | 4,767 | 656 | 662 | 661 |
| **Total cash used to acquire assets** | **1,082** | **4,767** | **656** | **662** | **661** |

DCB = Departmental Capital Budget

(a) Does not include annual finance lease costs. Includes purchases from current and previous years' DCB.

**Table 3.6: Statement of departmental asset movements
(Budget year 2022–23)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Buildings** $'000 | **Property, plant and equipment** $'000 | **Intangibles** $'000 | **Total** $'000 |
| **As at 1 July 2022** |  |  |  |  |
| Gross book value  | 1,854 | 1,196 | 3,904 | **6,954** |
| Gross book value - RoU | 7,875 | - | - | **7,875** |
| Accumulated depreciation/amortisation and impairment | (402) | (668) | (3,849) | **(4,919)** |
| Accumulated depreciation/ amortisation and impairment - RoU | (3,038) | - | - | **(3,038)** |
| **Opening net book balance** | **6,289** | **528** | **55** | **6,872** |
| **CAPITAL ASSET ADDITIONS** |  |  |  |  |
| **Estimated expenditure on new or replacement assets** |  |  |  |  |
| By purchase - appropriation equity | - | - | - | **-** |
| By purchase - appropriation ordinary annual services | 2,049 | 2,506 | 212 | **4,767** |
| By purchase - RoU | - | - | - | **-** |
| **Total additions** | **2,049** | **2,506** | **212** | **4,767** |
| **Other movements** |  |  |  |  |
| Depreciation/amortisation expense | (460) | (171) | (168) | **(799)** |
| Depreciation/amortisation expense - RoU | (767) | - | - | **(767)** |
| **Total other movements** | **(1,227)** | **(171)** | **(168)** | **(1,566)** |
| **As at 30 June 2023** |  |  |  |  |
| Gross book value | 3,903 | 3,702 | 4,116 | **11,721** |
| Gross book value - RoU | 7,875 | - | - | **7,875** |
| Accumulated depreciation/ amortisation and impairment | (862) | (839) | (4,017) | **(5,718)** |
| Accumulated depreciation/ amortisation and impairment - RoU | (3,805) | - | - | **(3,805)** |
| **Closing net book balance** | **7,111** | **2,863** | **99** | **10,073** |

RoU = Right-of-Use asset

**Table 3.7: Schedule of budgeted income and expenses administered on behalf of Government (for the period ended 30 June)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual**$'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate**$'000 | **2024–25 Forward estimate**$'000 | **2025–26 Forward estimate**$'000 |
| **EXPENSES ADMINISTERED ON BEHALF OF GOVERNMENT** |  |   |  |  |  |
| Suppliers | 1,396,321 | 1,579,416 | 1,670,875 | 1,773,067 | 1,950,173 |
| Grants | 372 | - | - | - | - |
| Employee benefits | 869 | - | - | - | - |
| Depreciation and amortisation | 1,933 | - | - | - | - |
| **Total expenses administered on behalf of Government** | **1,399,495** | **1,579,416** | **1,670,875** | **1,773,067** | **1,950,173** |
| **INCOME ADMINISTERED ON BEHALF OF GOVERNMENT** |  |   |  |  |  |
| **Revenue** |  |   |  |  |  |
| **Non-taxation** |  |   |  |  |  |
| Sales of goods and services | 1,468,979 | 1,583,885 | 1,675,333 | 1,772,513 | 1,949,607 |
| Interest  | 1,686 | 4,146 | 4,146 | 4,146 | 4,146 |
| Other non-tax revenue | - | 531 | 542 | 554 | 566 |
| **Total non-taxation revenue** | **1,470,665** | **1,588,562** | **1,680,021** | **1,777,213** | **1,954,319** |
| **Total revenues administered on behalf of Government** | **1,470,665** | **1,588,562** | **1,680,021** | **1,777,213** | **1,954,319** |
| **Total income administered on behalf of Government** | **1,470,665** | **1,588,562** | **1,680,021** | **1,777,213** | **1,954,319** |

**Table 3.8: Schedule of budgeted assets and liabilities administered on behalf of Government (as at 30 June)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual**$'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate**$'000 | **2024–25 Forward estimate**$'000 | **2025–26 Forward estimate**$'000 |
| **ASSETS ADMINISTERED ON BEHALF OF GOVERNMENT** |  |   |  |  |  |
| **Financial assets** |  |   |  |  |  |
| Cash and cash equivalents | 182,649 | 187,831 | 192,831 | 192,831 | 192,831 |
| Receivables | 47,830 | 47,830 | 47,830 | 47,830 | 47,830 |
| Investments | 138,973 | 143,119 | 147,265 | 151,411 | 155,557 |
| **Total financial assets** | **369,452** | **378,780** | **387,926** | **392,072** | **396,218** |
| **Non-financial assets** |  |   |  |  |  |
| Property, plant and equipment | 11 | 11 | 11 | 11 | 11 |
| Intangibles | 4,502 | 4,502 | 4,502 | 4,502 | 4,502 |
| Inventories | 115,177 | 115,177 | 115,177 | 115,177 | 115,177 |
| Other | 60,357 | 60,359 | 60,359 | 60,359 | 60,359 |
| **Total non-financial assets** | **180,047** | **180,049** | **180,049** | **180,049** | **180,049** |
| **Total assets administered on behalf of Government** | **549,499** | **558,829** | **567,975** | **572,121** | **576,267** |
| **LIABILITIES ADMINISTERED ON BEHALF OF GOVERNMENT** |  |   |  |  |  |
| **Payables** |  |   |  |  |  |
| Suppliers | 22,009 | 22,009 | 22,009 | 22,009 | 22,009 |
| Other | 125,671 | 125,671 | 125,671 | 125,671 | 125,671 |
| **Total payables** | **147,680** | **147,680** | **147,680** | **147,680** | **147,680** |
| **Total liabilities administered on behalf of Government** | **147,680** | **147,680** | **147,680** | **147,680** | **147,680** |

**Table 3.9: Schedule of budgeted administered cash flows (for the period ended 30 June)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual**$'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate**$'000 | **2024–25 Forward estimate**$'000 | **2025–26 Forward estimate**$'000 |
| **OPERATING ACTIVITIES** |  |   |  |  |  |
| **Cash received** |  |   |  |  |  |
| Commonwealth contributions | - | 531 | 542 | 554 | 566 |
| State and territory contributions | 1,467,456 | 1,583,885 | 1,675,333 | 1,772,513 | 1,949,607 |
| Interest | 1,833 | 4,146 | 4,146 | 4,146 | 4,146 |
| Net GST received | 133,262 | 178,598 | 188,940 | 200,496 | 220,523 |
| **Total cash received** | **1,602,551** | **1,767,160** | **1,868,961** | **1,977,709** | **2,174,842** |
| **Cash used** |  |   |  |  |  |
| Suppliers | 1,422,159 | 1,579,416 | 1,670,875 | 1,773,067 | 1,950,173 |
| Grant payments | 372 | - | - | - | - |
| Employees | 869 | - | - | - | - |
| Net GST paid | 133,254 | 178,598 | 188,940 | 200,496 | 220,523 |
| **Total cash used** | **1,556,654** | **1,758,014** | **1,859,815** | **1,973,563** | **2,170,696** |
| **Net cash from (or used by) operating activities** | **45,897** | **9,146** | **9,146** | **4,146** | **4,146** |
| **INVESTING ACTIVITIES** |  |   |  |  |  |
| **Cash received** |  |   |  |  |  |
| Proceeds from sale of investments | 67,132 | - | - | - | - |
| **Total cash received** | **67,132** | **-** | **-** | **-** | **-** |
| **Cash used** |  |   |  |  |  |
| Purchase of investments | 68,405 | 4,146 | 4,146 | 4,146 | 4,146 |
| Purchase of non-financial assets | 1,016 | - | - | - | - |
| **Total cash used** | **69,421** | **4,146** | **4,146** | **4,146** | **4,146** |
| **Net cash from (or used by) investing activities** | **(2,289)** | **(4,146)** | **(4,146)** | **(4,146)** | **(4,146)** |
| **Net increase (or decrease) in cash held** | **43,608** | **5,000** | **5,000** | **-** | **-** |
| Cash at beginning of reporting period | 138,696 | 182,647 | 187,831 | 192,831 | 192,831 |
| Cash from the OPA for: |  |   |  |  |  |
| - special accounts | 1,536,643 | 1,564,711 | 1,651,675 | 1,748,920 | 1,860,200 |
| - appropriations | 343 | 184 | - | - | - |
| - GST appropriations | 133,254 | 178,598 | 188,940 | 200,496 | 220,523 |
| Cash to the OPA for: |  |   |  |  |  |
| - special accounts | (1,536,633) | (1,564,711) | (1,651,675) | (1,748,920) | (1,860,200) |
| - GST appropriations | (133,262) | (178,598) | (188,940) | (200,496) | (220,523) |
| **Cash at end of reporting period** | **182,649** | **187,831** | **192,831** | **192,831** | **192,831** |

OPA = Official Public Account

**Table 3.10: Schedule of administered capital budget statement (for the period ended 30 June)**

This section is not applicable to the NBA.

**Table 3.11: Statement of administered asset movements (Budget year
2022–23)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Buildings** $'000 | **Property, plant and equipment** $'000 | **Intangibles** $'000 | **Total** $'000 |
| **As at 1 July 2022** |  |  |  |  |
| Gross book value  | - | 148 | 13,215 | **13,363** |
| Gross book value - RoU | - | - | - | **-** |
| Accumulated depreciation/amortisation and impairment | - | - | - | **-** |
| Accumulated depreciation/ amortisation and impairment - RoU | - | (137) | (8,713) | **(8,850)** |
| **Opening net book balance** | **-** | **11** | **4,502** | **4,513** |
| **CAPITAL ASSET ADDITIONS** |  |  |  |  |
| **Estimated expenditure on new or replacement assets** |  |  |  |  |
| By purchase - appropriation equity | - | - | - | **-** |
| By purchase - appropriation ordinary annual services | - | - | - | **-** |
| By purchase - internal resources | - | - | - | **-** |
| **Total additions** | **-** | **-** | **-** | **-** |
| **Other movements** |  |  |  |  |
| Depreciation/amortisation expense | - | - | - | **-** |
| Depreciation/amortisation expense - RoU | - | - | - | **-** |
| **Total other movements** | **-** | **-** | **-** | **-** |
| **As at 30 June 2023** |  |  |  |  |
| Gross book value  | - | 148 | 13,215 | **13,363** |
| Gross book value - RoU | - | - | - | **-** |
| Accumulated depreciation/amortisation and impairment | - | - | - | **-** |
| Accumulated depreciation/ amortisation and impairment - RoU | - | (137) | (8,713) | **(8,850)** |
| **Closing net book balance** | **-** | **11** | **4,502** | **4,513** |

RoU = Right-of-Use asset

1. For more information about the strategic direction of the NBA, refer to the current Corporate Plan, available at: www.blood.gov.au/about-nba [↑](#footnote-ref-1)
2. Fractionated products are those derived from human plasma while recombinant products are those manufactured through commercial scale expression of proteins from cell lines modified using recombinant gene technology. [↑](#footnote-ref-2)
3. Refer to the ACSQHC chapter in these Portfolio Budget Statements for further information on the work of this entity. [↑](#footnote-ref-3)
4. For further information about the criteria refer to the Ig governance website, available at: www.criteria.blood.gov.au [↑](#footnote-ref-4)
5. Performance reporting and benchmarking information is published progressively throughout the year as data collation and analysis is completed, and such reporting and information is also included annually in the NBA Annual Report. [↑](#footnote-ref-5)
6. Ibid. [↑](#footnote-ref-6)